Inhaled insulin put to the test

A new inhaled insulin formula is not as good as subcutaneous injection at reducing HbA1C, but it provides better control of hypoglycaemia, according to a systematic review.

Data from 12 trials with 5,300 type 1 and 2 diabetes patients shows subcutaneous insulin achieves greater the HbA1C decreases from baseline compared with Afrezza, an inhaled insulin approved by the FDA in 2014.

And a greater